Zobrazeno 1 - 10
of 347
pro vyhledávání: '"Lawrence Gould"'
Autor:
A Lawrence Gould, Robert K Campbell, John W Loewy, Robert A Beckman, Jyotirmoy Dey, Anja Schiel, Carl-Fredrik Burman, Joey Zhou, Zoran Antonijevic, Eva R Miller, Rui Tang
Publikováno v:
PLoS ONE, Vol 17, Iss 6, p e0265712 (2022)
The FDA's Accelerated Approval program (AA) is a regulatory program to expedite availability of products to treat serious or life-threatening illnesses that lack effective treatment alternatives. Ideally, all of the many stakeholders such as patients
Externí odkaz:
https://doaj.org/article/df7c2634c3974c088d761e2046bb8771
Publikováno v:
Journal of Biopharmaceutical Statistics. 32:832-857
Biomedical applications such as genome-wide association studies screen large databases with high-dimensional features to identify rare, weakly expressed, and important continuous-valued features for subsequent detailed analysis. We describe an exact,
Autor:
A. Lawrence Gould
Publikováno v:
Biometrical Journal. 61:1141-1159
Successful pharmaceutical drug development requires finding correct doses. The issues that conventional dose-response analyses consider, namely whether responses are related to doses, which doses have responses differing from a control dose response,
Autor:
A. Lawrence Gould, Robert K. Campbell, John W. Loewy, Robert A. Beckman, Jyotirmoy Dey, Anja Schiel, Carl-Fredrik Burman, Joey Zhou, Zoran Antonijevic, Eva R. Miller, Rui Tang
Publikováno v:
PloS one. 17(6)
The FDA’s Accelerated Approval program (AA) is a regulatory program to expedite availability of products to treat serious or life-threatening illnesses that lack effective treatment alternatives. Ideally, all of the many stakeholders such as patien
Historical information can be used to improve the efficiency of the development process for a medical product (drug, vaccine, or device) and to provide an approach to address indirectly clinically important questions that cannot be addressed directly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ab0d8668b7c1820b91d3608403dc14f
https://doi.org/10.1201/9781315099798-2
https://doi.org/10.1201/9781315099798-2
Autor:
A. Lawrence Gould
Publikováno v:
Statistics in Medicine. 37:2667-2689
Patients in large clinical trials and in studies employing large observational databases report many different adverse events, most of which will not have been anticipated at the outset. Conventional hypothesis testing of between group differences fo
Autor:
Lawrence Gould, Jeffrey
Este libro presenta casos de experimentos sociales en El Salvador, Nicaragua y Uruguay. En estos espacios, donde florecía la comunicación horizontal y multiclasista, el concepto de utopías menores de Jay Winter es apropiado. Esta obra rastrea lo q
Autor:
A. Lawrence Gould, William B. Wang
Publikováno v:
Statistics in Medicine. 36:92-104
The development of drugs and biologicals whose mechanisms of action may extend beyond their target indications has led to a need to identify unexpected potential toxicities promptly even while blinded clinical trials are under way. One component of r
Autor:
A. Lawrence Gould
Publikováno v:
Statistics in Medicine. 35:5561-5578
Conventional practice monitors accumulating information about drug safety in terms of the numbers of adverse events reported from trials in a drug development program. Estimates of between-treatment adverse event risk differences can be obtained read
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.